glp-1 reviews receptor agonists for individualized treatment of type 2 diabetes mellitus The promise and peril of
Description
Promising clinical trial data suggests big opportunity with Eli Lilly's retatrutide GLP-1 candidate.
However, renal effects of GLP-1 in heart failure (HF) has not been elucidated
Key Findings: - Increased risk of going over recommended weight gain limits - Higher chances of preterm birth (from 13% to 17%) - Rising cases of gestational diabetes (15% to 20%) - Nearly half faced high blood pressure issues While baby sizes and C-section rates remained similar, the impact on maternal health is significant
GLP-1 weight loss therapy doesn't have to drain your budget
With the right foodsespecially those high in protein and fiberyou can naturally stimulate GLP-1 production
